Výsledky vyhledávání - "Sophie Matharan"

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder

Autor: Sergey Mosolov, F. Picarel-Blanchot, Valérie Olivier, Livia Vavrusova, Antti Ahokas, István Bitter, Michael Bauer, Sophie Matharan, Dan J. Stein, Jon Paul Khoo, Marek Jarema, Michael Van Ameringen, Cyril Hӧschl, Christian de Bodinat

Publikováno v: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 28(8)

Treatment of severely symptomatic patients with generalized anxiety disorder (GAD) raises particular concerns for clinicians. This 12-week double-blind study evaluated the efficacy of agomelatine (25–50 mg/day) in the treatment of patients with sev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27c53ffb1887872f8e49be292614a456
https://pubmed.ncbi.nlm.nih.gov/30135032

Zobrazit plný text záznamu

Discriminating between Anxious and Non-Anxious Subjects Using the Toronto Hospital Alertness Test

Autor: Lucie Truffaut, Colin M. Shapiro, Valérie Olivier, Sophie Matharan

Publikováno v: Frontiers in Psychiatry

Background: Alertness designates the internal feeling of wakefulness or arousal and is often described to be linked to the level of anxiety. An adequate level of anxiety favouring the alertness needed to deal with a faced specific situation efficient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffdbb96bd963295f79afcdb9dd264dce

Zobrazit plný text záznamu

How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine

Autor: Sophie Matharan, Christian de Bodinat, Michel Lejoyeux

Publikováno v: CNS Spectrums. 20:29-38

Objective/introductionThe present trial informs clinicians about switching conditions with the antidepressant agomelatine after the failure of a treatment with either paroxetine or venlafaxine.MethodsThe total number of discontinuation-emergent sympt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a88d31fc73518d28f4ca49dbb15ce8
https://doi.org/10.1017/s1092852913000813

Zobrazit plný text záznamu

Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalized anxiety disorder

Autor: Michael Bauer, Sophie Matharan, Marek Jarema, Cyril Höschl, Antti Ahokas, Sergey Mosolov, Dan J. Stein, István Bitter, Jon Paul Khoo, F. Picarel-Blanchot, D.M. Van Ameringen, Valérie Olivier, Livia Vavrusova

Publikováno v: European Neuropsychopharmacology. 27:S1003

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8d26e27eac8c6b816c877ec967bd651
https://doi.org/10.1016/s0924-977x(17)31762-5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání